A phase II study of Erlotinib plus Pemetrexed for previously treated Non Small Cell Lung Cancer
Phase 2
- Conditions
- on-Small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000007397
- Lead Sponsor
- Kochi University, School of Medicine, Department of Hematology and Resporatory Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis 2) Patients who have previously treated with EGFR-TKI and / or pemetrexed 3) Patients with active severe infections 4) Impossible cases with oral administration 5) Patients with active opthalmological disease 6) Pregnancy or lactation 7) Patients with symptomatic brain metastasis 8) Patients with active concomitant malignancy 9) Patients with uncontrollable complications (e.g. uncontrollable heart disease, severe arrhythmia, continuous diarrhea) 10) Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rseponse rate
- Secondary Outcome Measures
Name Time Method disease control rate, progression free survival, overall survival, evaluation of safety